WANG Jinhua Principal Investigator

Department :

National center for pharmaceutical screening

Platform :

Beijing Key Laboratory of Drug Targets Identification and Drug Screening

Contact Details

Wang Jinhua's group
Brief Introduction

Education and career

03/2015-present Professor, Institute of Materia Medica, CAMS & PUMC

02/2007-03/2015 Research Associate, Medical scientist, Assistant professor, faculty. Department of Molecular Oncology, John Wayne Cancer Institute, USA

07/2006-10/2007  Research Associate, Department of Neuropathology, Case Western Reserve University, USA

08/1999-06/2004 Ph.D., Peking University

08/1991-07/1996 B.S., The Capital University of Medical Science

Research area

1. Studying the mechanism and drug targets of cancers.

2. Establishing high through-put screening models for cancer drugs.

3. Evaluating active compounds in vitro and in vivo.

4. Looking for and developing new drugs by using artificial intelligence, bioinformatics and network pharmacology.



1. MELK is an oncogenic kinase essential for metastasis, mitotic progression, and programmed death in lung carcinoma. Signal Transduct Target Ther. 2021 6(1):83-94.

2. Thioredoxin-like 2 regulates human cancer cell growth and metastasis via redox homeostasis and NF-κB signaling. Journal of Clinical Investigation. 2011;121(1):212-225.

3. 3-O-Acetyl-11-keto-β-boswellic acid ameliorated aberrant metabolic landscape and inhibited autophagy in glioblastoma. Acta Pharmaceutica Sinica B, 2020, 10(2): 301-12.

4. Sinomenine ester derivative inhibits glioblastoma by inducing mitochondria-dependent apoptosis and autophagy by PI3K/AKT/mTOR and AMPK/mTOR pathway. Acta Pharmaceutica Sinica B, 2021

5. The biology, function, and applications of exosomes in cancer. Acta Pharmaceutica Sinica B (In press).

6. Members of FOX family could be drug targets of cancers. Pharmacol Ther. 2018;181:183-196.

7. The Sphingosine Kinase-1 / Sphingosine-1-Phosphate Axis in Cancer: Potential Target for Anticancer Therapy. Pharmacology & Therapeutics. 2019; 195:85-99.

8. EZH2 regulates expression of FOXC1 by mediating H3K27me3 in breast cancers. Acta Pharmacol Sin. 2020; 14.

9. Avasimibe exerts anticancer effects on human glioblastoma cells via inducing cell apoptosis and cell cycle arrest. Acta Pharmacologica Sinica, 2020.

10. Role of FOXC1 in regulation of basal-like/triple-negative breast cancer. Journal of Clinical Oncology. 2009; 27: 562S (No 15S, Part I of II).

11. Diagnosis of Basal-Like Breast Cancer Using a FOXC1-Based Assay. J Natl Cancer Inst. 2015 Jun 3;107(8).

12. RASAL2 activates RAC1 to promote triple-negative breast cancer progression. J Clin Invest. 2014; 124(12):5291-5304.

13. Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF-κB Pathway in Melanoma. Clin Cancer Res. 2017; 23(16):4831-4842.

14. FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. Cancer Research. 2010; 70(10):1-7.

15. JNK, essential for anticancer therapy-induced apoptosis promotes cancer breast progession. Cancer Research. 2009; 69( suppl.):(2).

16. Acquire resistance to braf-inhibitor by increasing EGFR expression. Journal of Investigative Dermatology. 2015; 135:532-541.

17. FOXC1 regulates the functions of human basal-like breast cancer cells by activating NF-kB signaling. Oncogene, 2012;31(45):4798-802.

18. RASSF8 Regulates Progression of Cutaneous Melanoma through Nuclear Factor-κb. Oncotarget, 2015:6:30165-30177.

19. P-REX1 amplification promotes progression of cutaneous melanoma via the PAK1/P38/MMP-2 pathway.  Cancer Lett. 2017;407:66-75.

20. B7-H3 Associated with Tumor Progression and Epigenetic Regulatory Activity in Cutaneous Melanoma. Journal of Investigative Dermatology. 2013; 133(8):2050-8.

21. Protein Tyrosine Phosphatase UBASH3B is Overexpressed in Triple-Negative Breast Cancer and Promotes Invasion and Metastasis. Proc Natl Acad Sci U S A. 2013; 110(27):11121-6.

22. Antiangiogenesis Combined Photothermal Therapy in the Second Near Infrared Window at Laser Powers Below the Skin Tolerance Threshold. Nano-Micro Lett. (2019) 11:93.

23. Epigenome-wide DNA Methylation Landscape of Melanoma Progression to Brain Metastasis Reveals Aberrations on Homeobox D Cluster Associated with Prognosis. Human Molecular Genetics, 2013; 23(1): 226-38.

24. MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A. Oncotarget. 2015:6(5):3211-24.

25. GD3s,a novel drug target of cancer. Acta Pharmaceutica Sinica B. 2018; 8(5):713-720.

26. 3-O-acetyl-11-keto-β-boswellic acid exerts anti-tumor effects in glioblastoma by arresting cell cycle at G2/M phase. Journal of Experimental & Clinical Cancer Research. 2018; 37(1):132.  

27. miR-29c plays a suppressive role in breast cancer by targeting the TIMP3/STAT1/FOXO1 pathway. Clinical Epigenetics. 2018;10:64.

28. Overexpression of NSUN2 by DNA hypomethylation is associated with metastatic progression in human breast cancer. Oncotarget. 2017; 8(13):20751-20765.

29. Research progress on the Forkhead Box C1. Oncotarget, 2017; 9(15):12471-12478.

30. Overexpression of NSUN2 by DNA hypomethylation is associated with metastatic progression in human breast cancer. Oncotarget. 2017 Mar 28;8(13):20751-20765.

31. FOXC1 promotes melanoma by activating MST1R/PI3K/AKT pathway. Oncotarget. 2016; 7(51):84375-84387.

32. Withaferin A triggers G2/M arrest and intrinsic apoptosis in glioblastoma cells via ATF4‐ATF3-CHOP axis. Cell Prolif. 2019; 23:e12706.

33. Sustained JNK Activity Promotes Epithelial-Mesenchymal Transition, Invasion, and Survival of Breast Cancer Cells by Regulating ERK Activation. Molecular Cancer Research, 2010; 8(2):266-277.

34. Trefoil factor 1 (TFF1) is a potential prognostic biomarker with functional significance in breast cancers. Biomedicine & Pharmacotherapy, 2020, 124(109827).

35. Elesclomol, counteracted by Akt survival signaling, enhances the apoptotic effect of chemotherapy drugs in breast cancer cells. Breast Cancer Research and Treatment, 2010; 121(2):311-21.


1. "Experimental Pharmacology (2nd Edition)", Vice chief Editor, Higher Education Press, published in 2020. Published in 2021.

2. "Nature small molecule drugs from plants" editor. Springer Nature Singapore Pte Ltd. and People's Medical Publishing House, published in 2019.

3. "China Medical Science and Technology Development Report", editor. published in 2019 by Science Press.

4. Associate Editor of "Natural Small Molecule Drugs-Small Molecule Drugs Derived from Plants". People's Medical Publishing House, published in 2018.

5. "Summary and Review of Ancient and Modern Research on the "Poison" of Chinese Medicinal Materials", editorial board member. China Medical Science and Technology Press, published in 2018.

6. Editorial Board Member of "Encyclopedia of Diabetes Life". Science Press, published in 2018.

7. "Talking about Diabetes", editorial board. Science Press, published in 2017.

8. "The Encyclopedia of Salvia". ISBN:978-7-117-09935-6/R.9936, editor. People's Medical Publishing House, published in 2008.

Honors & Awards